Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: Findings of a retrospective audit

Women and Birth

Volumn 24, Issue 1, 2011, Pages 32-39

  Blandthorn, Julie ^a   Forster, Della A ^a,b   Love, Veronica ^c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c O'Connell Family Centre   (Australia)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence syndrome; Pregnancy; Substance use

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE;

ADDICTION; ADULT; ARTICLE; CANNABIS ADDICTION; ENVIRONMENTAL EXPOSURE; FEMALE; GESTATIONAL AGE; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL CARE; NEWBORN CARE; PERINATAL PERIOD; PREGNANCY OUTCOME; PRENATAL CARE; PRESCRIPTION; PRIORITY JOURNAL; SUBSTANCE ABUSE; SUBSTITUTION THERAPY; TOBACCO; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL HEALTH SERVICES; MATERNAL WELFARE; MEDICAL AUDIT; MEDICAL RECORDS; METHADONE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL CARE; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251594464     PISSN: 18715192     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.wombi.2010.07.001     Document Type: Article

References (50)

1. NSW Department of Health. National clinical guidelines for the management of drug use during pregnancy, birth, and the early development years of the newborn. Commissioned by the Ministerial Council on Drug Strategy: NSW; 2006.
2. Winklbaur B., Jung E., Fischer G. Opioid dependency and pregnancy. Curr Opin Psychiatry 2008, 21:255-259.
3. Fischer G., Kopf N. Review of the literature on pregnancy and psychosocially assisted pharmacotherapy of opioid dependence (including withdrawal management, agonist and antagonist maintenance therapy and adjuvant pharmacotherapy). Third meeting of the technical development group (TDG) for the WHO guidelines for psychosocially assisted pharmacotherapy 2007, Geneva, Switzerland.
4. O'Donnell M.O., Nassar N., Leonard H., Hagan R., Matthews R., Patterson Y., et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 2009, 123:e614-e621.
5. Kaltenbach K., Berhella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin 1998, 25(1):139-151.
6. Ostrea E.M., Brady M., Gause S., Raymundo A.L., Stevens M. Drug screening of newborns by Meconium analysis: a large scale prospective epidemiologic study. Pediatrics 1992, 89(1):107-113.
7. National Institute on Drug Abuse. Consensus panel on effective medical treatment of opiate addiction. JAMA 1998;280:1936-43.
8. NSW Department of Health. Background papers to the National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn. Commissioned by the Ministerial Council on Drug Strategy under the Cost Shared Funding Project; 2006: http://www.health.nsw.gov.au/.
9. Ludlow J., Evans S., Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynecol 2004, 44(4 (August)):302-306.
10. Burns L., Mattick R.P., Lim K., Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007, 102(2 (February)):264-270.
11. Drug Policy Alliance. Methadone maintenance treatment. Lindesmith Library; 2010.
12. Ward J, Mattick RP, Hall W. The effectiveness of methadone maintenance treatment: an overview. In Drug use in Australia. Hamilton, Ritter, 2004 Editor. Melbourne: Oxford, University Press; 1998.
13. Center for Substance Abuse Treatment. State treatment methadone guidelines (Treatment improvement protocol series, 1). Rockville, MD: U.S. Department of Health and Human Services, Editor; 1993.
14. Finnegan L.P. Treatment issues for opioid-dependant women during the perinatal period. J Psychoactive Drugs 1991, 23(2):191-201.
15. Health Canada. Prepared by Jameison, Beals, Lalonde and Associates Inc. for the Office of Canada's Drug Strategy, Literature review-methadone maintenance treatment. Health Canada, Editor; 2002. p. 7-13, 55-9, http://www.cds-sca.com/.
16. Fischer G. Treatment of opioid dependence in pregnant women. Addiction 2000, 95:1141-1144.
17. Jarvis M.A.E., Schnoll S.H. Methadone use in pregnancy. NIDA Res Monogr 1995, 149:58-77.
18. Wilbourne P., Wallerstedt C., Dorato V. Clinical management of methadone dependence during pregnancy. J Perinat Neonatal Nurs 2001, 14(4 (March)):26-45.
19. Doberczak T.M., Kandall S.R., Friedman P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993, 81:936-940.
20. National Guidelines Clearinghouse. Medication-assisted treatment for opioid addiction in opioid treatment programs: medication assisted treatment for opioid addiction during pregnancy.; 2005. http://www.guideline.gov/.
21. Finnegan L.P., Wapner R.J. Narcotic addiction in pregnancy. Drug use in pregnancy 1987, Lea and Febigner, Philadelphia. I. Neibyl (Ed.).
22. Martin J., Payte J., JE Z. Methadone maintenance treatment. A primer for physicians. J Psychoactive Drugs 1991, 23:165-176.
23. Jones H.E., Johnson R.E., Jasinksi D.R., O'Grady K.E., Chisholm C.A., Choo R.E., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependant patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79. p. 1-10.24.
24. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., et al. Methadone versus Buprenorphine in pregnant addicts: a double blind, double dummy comparison study. Addiction 2006, 101:275-281.
25. Bartu A, Hamilton D, Doherty DA. Buprenorphine and pregnancy: Australian and international outcomes. In: Abstract from Perinatal Society of Australia and New Zealand Conference. J Perinat Child Health Editor 2009;45(Suppl. 1 (April)):A11.
26. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. The Cochrane Library; 2005(3). http://www.nichd.nih.gov/COCHRANE/Osborn8/OSBORN.HTM.
27. The Women's (The Royal Women's Hospital, M). Clinical practice guidelines for babies at risk of neonatal abstinence syndrome (NAS). WADS, Editor: Melbourne, 2008. http://www.thewomens.org.au/.
28. McCarthy J.J., Leamon M.H., Parr M.S., Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005, 193(3 (September)):606-610.
29. Choo R.E., Huestis M.A., Schroeder J.R., Shin A.S., Jones A.H. Neonatal abstinence syndrome in methadone exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004, 75:253-260.
30. Kandall S.R. Treatment options for drug-exposed infants. Res Monogr 1995, 149:78-99.
31. Lejeune C., Simmat-Durand L., Gourrier L., Aubisson S. Prospective multiobservational study of 260 infants born to 259 opiate-dependant mothers on methadone or high dose buprenorphine substitution. Drug Alcohol Depend 2006, 82:250-257.
32. Finnegan L.P. Neonatal abstinence syndrome: assessment and pharmacotherapy. Current therapy in neonatal-perinatal medicine 1990, BC Decker, Ontario. N. Nelson (Ed.).
33. Corporation M. Microsoft excel 2000.
34. Corporation S. STATA 8.0 statistics/data analysis. College Station. Texas: S. Corporation, Editor; 2003.
35. Finnegan LP. Perinatal drug addiction: sequelae and challenges in meeting the needs of women and children. In: International conference of drug dependence, maternity and childhood, international center for advancement of addiction treatment. Turin, Italy. 2000. http://www.opiateaddictionrx.info/special/pregnancy.html.
36. Kaltenbach K, Silverman N, Wapner R. Methadone maintenance during pregnancy, state methadone treatment guidelines: center for substance abuse treatment, Editor. U.S. Department of Health Services: Rockville, MD; 1992. p. 85-93.
37. Tobin MC. Lost opportunity or lifeline? Women with substance abuse issues and their perceptions of the barriers to pregnancy care. Women's alcohol and drug service. Royal Women's Hospital. Unpublished; 2005.
38. Johnson K, Gerada C, GA. Substance misuse during pregnancy. Br J Psychiatry 2003;183:187-9.
39. Van Meurs K. Cigarette smoking, pregnancy and the developing fetus. 1999. p. 3. http://med.stanford.edu/?medicalreview/smrp14-16pdf.
40. Lambers D., Clark K. The maternal and fetal physiological effects of nicotine. Semin Perinatol 1996, 20(2):115-126.
41. Kuczkowski K.M. The effects of drug use on pregnancy. Curr Opini Obstet Gynecol 2007, 19(6 (December)):578-585.
42. Gillogley K.M., Evans A.T., Hanson R.L., Samuels S.J., Batra K.K. The perinatal impact of cocaine, amphetamine and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol 1990, 163:1535-1542.
43. Jansson L.M., Svikis D., Leo J.J., Paluzzi P., Rutigliano P., Hackerman F. Pregnancy and addiction: a comprehensive care model. J Subst Abuse Treat 1996, 13:321-329.
44. Keen J., Alison L.H. Drug misusing parents: key points for health professionals. Arch Dis Child 2001, 85:296-299.
45. Siney C., Kidd M., Walkinshaw S., Morrison C., Manasse P. Opiate dependency in pregnancy. Br J Midwifery 1995, 3:69-73.
46. Broekhuizen F.F., Utrie J., Van Mullen V. Drug use or inadequate prenatal care? Adverse pregnancy outcomes in an urban setting. Am J Obstet Gynecol 1992, 166(6 part 1 (June)):1747-1756.
47. Shaw N.J., McIvor L. Neonatal abstinence syndrome after maternal methadone treatment. Arch Dis Child 1994, 71:F203P-F205.
48. American Academy of Pediatrics Committee on drugs. Neonatal drug withdrawal. Pediatrics 1983;72:895-902.
49. Seligman N.S., Salva N., Hayes E.J., Dysart K.C., Pequignot, Baxter J.K., et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008, 199:396.e1-396.e7.
50. Coghlan D., Milner M., Clarke T., Lambert I., McDermott C., McNally M., et al. Neonatal abstinence syndrome. Ir Med J 1999, 92(1):232-236.